## Scanfil

## **Company report**

8/8/2021 11:15



Antti Viljakainen +358 44 591 2216 antti.viljakainen@inderes.fi



**Joonas Korkiakoski** +358 40 1828 660 joonas.korkiakoski@inderes.fi



**Inderes Corporate customer** 



## Confidently toward H2 and CMD

We reiterate our accumulate recommendation for Scanfil and revise our target price to EUR 8.75 (previously EUR 8.60). Last Friday, Scanfil published its Q2 report which paints a neutral picture. The company's demand outlook for this year seems good and the biggest issues lie in the availability of materials. The share valuation has gone up justifiably, but growth in earnings and dividends bring the expected return to the level of required rate of return and a positive acquisition option (incl. the fire power in the balance sheet) make the overall expected return positive.

#### Operative profitability was lower than expected in Q2, which we don't find too dramatic

In Q2, Scanfil's turnover grew by 11% to EUR 173 million, which exceeded both our and the consensus estimates. Examining the revenue growth is made complicated by certain exceptional and billing-related items but we expect that the comparable growth in Q2 was slightly over 6%. In our view, this level is slightly shaky, given the strong market situation. However, Scanfil's customer base contains several post-cyclical elements. The operating profit margin of 6.1% was quite clearly below expectations and was also slightly lower than Scanfil's normal level. The operating profit was naturally weakened by temporary low-margin sales, but moving the production of the Hamburg factory that's being closed down added an extra burden. On a smaller scale, the different timing of cost inflation and pricing may have been a factor too. The lower lines of the income statement were mostly in line with estimations, and reflecting this, earnings per share at EUR 0.13 was a cent below our estimate. In Q2, given the issues with working capital, the cash flow was weak. This, however, should normalize partially toward the end of the year.

#### We only made small changes to the big picture

Scanfil reiterated its guidance for the current year in the Q2 report, in which turnover is EUR 630-680 million and adjusted operating profit EUR 41-46 million. As expected, the company also warned about uncertainties related to the pandemic and the delivery capacity of the supply chain in particular. In addition, the comments on the demand for the rest of the year were very positive. The reiteration of the guidance was expected and we estimate that Scanfil reaches the guidance levels. We have not made significant changes to our estimates for the current year and the changes we made for the next few years were marginal but positive. We expect that Scanfil's operating profit remains growing steadily, when the turnover grows organically through the market situation and small market share gains at a moderate pace and the company gradually improves its efficiency (e.g. closing down the Hamburg factory brings EUR 2.5 million in savings, mainly for 2022). In the short term, Scanfil's biggest risks revolve around material availability and in the long term, around the development of (investment-driven) demand that is tied to the development of the global economy.

#### Expected return and acquisition option make the overall outlook positive

P/E ratios for 2021 and 2022 based on our estimates are 16x and 15x, while the corresponding EV/EBIT ratios are 12x and 11x. The valuation has clearly surpassed the company's low 5-year medians and to a relative premium of 5-15%. Given Scanfil's profitable growth of the past few years and the lowered customer risk, we find this justifiable, but don't see room for stretching the multiples any higher. The expected return for the next 12 months consists of growth in earnings and dividend and is on the level with the required rate of return, and the acquisition option (incl. the fire power in the balance sheet) make the overall expected return slightly positive.

#### Recommendation

Accumulate

(previous Accumulate)

**EUR 8.75** 

(previous EUR 8.60)

Share price:

8.30



#### **Key indicators**

	2020	<b>2021</b> e	<b>2022</b> e	2023e
Revenue	595	672	680	695
growth %	3%	13%	1%	2%
EBIT adj.	39.1	43.4	47.0	48.4
EBIT % adj.	6.6%	6.5%	6.9%	7.0%
Net profit	36.9	34.1	36.7	37.4
EPS (adj.)	0.50	0.53	0.57	0.58
P/E (adj.)	13.0	15.7	14.6	14.3
P/B	2.3	2.6	2.3	2.1
Dividend yield %	2.6%	2.3%	2.5%	2.8%
EV/EBIT (adj.)	11.2	12.6	11.1	10.4
EV/EBITDA	7.2	9.5	8.6	8.1
EV/Sales	0.7	0.8	0.8	0.7

Source: Inderes

#### Guidance

(Unchanged)

Scanfil estimates that in 2021, its turnover is EUR 630-680 million and adjusted operating profit EUR 41-46 million.

#### Share price



#### Revenue and EBIT %



#### **EPS** and dividend



Source: Inderes

## M

#### Value drivers

- Organic growth with the market and key customers
- Accelerating growth through M&A
- Strong financial track record
- Increase in acceptable valuation



#### **Risk factors**

- Demand comes mainly from somewhat cyclical sectors
- · Greater competition
- · Limited pricing power
- Supply chain and material availability challenges

Valuation	2021e	2022e	<b>2023</b> e
Share price	8.30	8.30	8.30
Number of shares, millions	64.5	64.5	64.5
Market cap	535	535	535
EV	546	521	503
P/E (adj.)	15.7	14.6	14.3
P/E	15.7	14.6	14.3
P/FCF	26.9	14.2	17.2
P/B	2.6	2.3	2.1
P/S	0.8	0.8	0.8
EV/Sales	8.0	0.8	0.7
EV/EBITDA	9.5	8.6	8.1
EV/EBIT (adj.)	12.6	11.1	10.4
Payout ratio (%)	35.9 %	36.9 %	39.7 %
Dividend yield-%	2.3 %	2.5 %	2.8 %

## Growth in earnings slower than estimated in Q2 because of profitability

#### Estimations vs. outcome Q2'21

- Scanfil's revenue grew in Q2 by 11% to EUR 173 million, which exceeded both our and the consensus estimates. In Q2, the turnover includes EUR 5.4 million of new, low-margin temporary sales related to supply chain management.
   Moreover, there's still EUR 2 million of low-margin intermediated sales related to the factory that was sold to China (Q2: EUR -10 million vs. Q2'20).
- Of the renewed customer segments, when adjusted from temporary and intermediated sales Advanced Consumer Applications, Energy&Cleantech and Medtech&Life Science had grown, whereas Connectivity and Automation&Safety declined.
- In Q2, Scanfil's operating profit was EUR 10.6 million, which was 10% lower than our and the consensus estimates. This leads into an operating profit margin of 6.1%, which is satisfactory when compared to Scanfil's past few years. Profitability was weakened by the above mentioned low-margin sales and the relocating of the Hamburg factory's production.
- On the lower lines of the income statement, financing costs and taxes were slightly lower than we estimated and reflecting this, EPS of EUR 0.13 was a cent lower than in our estimates.
- Scanfil's operational cash flow in Q2 was roughly zero, when seasonal factors, difficult materials situation and inflation tied up working capital. We expect that the cash flow increases toward the end of the year, as is typical for the company.

#### Operational result drivers Q2'21

- In Q2, the sales of Scanfil were mainly supported by increasing demand.
   Of the five customer segments, three grew in Q2, which means that the growth relies on fewer segments than we expected.
- In our estimate, comparable growth was a bit over 6%, which, given the strong market situation, is a slightly shaky level. In our opinion, however, Scanfil's customer portfolio is partly of post-cyclical nature.
- In Q2, the company's relative profitability was weakened by both the
  effects of the temporary, zero-to-low margin China sales and the extra
  expenses (EUR "few hundred thousand) from closing down the Hamburg
  factory. In turn, problems with material prices and availability caused only
  slight burden on the operating profit in Q2.
- In the end of Q2, the company's net debt ratio decreased to 13% (Q2'20: 27%), which is easily within our estimated comfort zone for Scanfil. Thus, there's plenty of room for inorganic growth.

Estimates	Q2'20	Q2'21	Q2'21e	Q2'21e	Conse	nsus	Difference (%)	2021e
MEUR / EUR	Comparison	Actualized	Inderes	Consensus	Low	High	Act. vs. inderes	Inderes
Revenue	156	173	170	163	156 -	170	2%	672
EBIT	10.2	10.6	11.7	11.3	11.0 -	12.0	-9%	43.4
PTP	9.6	10.4	11.5	11.0	11.0 -	11.5	-9%	42.0
EPS (reported)	0.13	0.13	0.14	0.14	0.12 -	0.14	-9%	0.53
Revenue growth-%	9.0 %	11.2 %	9.3%	4.8 %	0.3 % -	9.3 %	1.9 pp	12.9 %
EBIT-% (adj.)	6.6 %	6.1%	6.9 %	7.0 %	7.1% -	7.1%	-0.8 pp	6.5 %

Source: Inderes & Reuters (consensus)

## We only made small changes to the big picture

#### Estimate changes 2021e-2023e


- Scanfil reiterated the guidance that was raised in June at EUR 630-680 million turnover and EUR 41-46 million adjusted operating profit for 2021.
   As expected, the company also warned about uncertainties related to the pandemic and the delivery capacity of the supply chain (in particular semiconductors). The comments on the demand for the rest of the year were strong or even slightly stronger than we expected.
- We haven't changed our estimates for the rest of 2021 after the Q2 report, as the slight raises in the estimates for the rest of the year make up for the Q2 undershoot. The main risks revolve around material availability, but based on the company's comment, July was already slightly better in this sense. Scanfil can compensate the growing price pressure by raising prices rather quickly. This does not concern Scanfil's own pricing power, but the typical contract structures of contract manufacturers that work both ways (i.e. decrease in material prices also lowers own prices).
- We raised our growth estimates marginally based on the industrial demand that seems good and Scanfil's own competitiveness.
- We didn't make changes to the lower lines of the income statement nor our dividend estimates.

#### Operational result drivers 2021-2023e:

- In 2021, we expect that Scanfil's turnover grows by 13% to EUR 672
  million and adjusted operating profit by 11% to EUR 43.4 million. The
  earnings growth is a result of growth in turnover that reflects the market
  that is picking up and moderate market share gains of current customers.
- Profitability, even with the high volume this year won't likely be a great success. Behind this is the relocating of the production of the Hamburg factory, large amount of low-margin temporary sales and a difficult material situation on a global level.
- In 2022-2023, we expect that the company's volume growth to continue
  with the support of key customers, progressing customer acquirement
  and the development of own competitiveness (incl. most of the savings
  from closing down the Hamburg factory support the result of 2022).
- We expect that the company meets its profitability target in 2023, whereas we expect it to meet its growth target (turnover organically over EUR 700 million in 2023) at the run rate level in early 2024, as long as the macroeconomic situation remains stable.

Estimate revisions MEUR / EUR	<b>2021e</b> Old	2021e New	Change %	<b>2022e</b> Old	2022e New	Change %	<b>2023e</b> Old	2023e New	Change %
Revenue	655	672	3%	675	680	1%	690	695	1%
EBITDA	57.9	57.7	0%	60.3	60.7	1%	61.8	62.2	1%
EBIT (exc. NRIs)	44.0	43.4	-1%	46.5	47.0	1%	48.0	48.4	1%
EBIT	44.0	43.4	-1%	46.5	47.0	1%	48.0	48.4	1%
PTP	42.6	42.0	-1%	45.9	46.4	1%	47.5	47.9	1%
EPS (excl. NRIs)	0.53	0.53	0%	0.56	0.57	1%	0.58	0.58	1%
DPS	0.19	0.19	0%	0.21	0.21	0%	0.23	0.23	0%

## Risk profile of the business model



## **Expected return is barely sufficient**

#### Multiples are still reasonable

In our estimate, Scanfil's P/E ratios for 2021 and 2022 are 16x and 15x, while the corresponding EV/EBIT ratios are 12x and 11x. Given the company's improving performance, we expect the dividend yield for the next few years to be between 2-3%. However, we don't deem dividends very significant for Scanfil's total expected returns, as its profile is one of a growth company, even if the dividends of the next few years make up a solid part of the required rate of return. The current earnings-based valuation is quite clearly above historical medians. We find this justified, when Scanfil's strengthened performance level and the risk profile that has decreased through acquisitions (incl. more diverse customer portfolio) are taken into considered. With this in mind, we don't see the multiples unreasonably high.

Scanfil's P/B ratio 2.6x is reasonable when compared to the adjusted ROE of the last five years of 18% and the earnings growth. With these numbers, Scanfil's retrospective static earnings return is 7%, which is only slightly lower than the ROE requirement. Thus, the company's good short and long-term growth potential is not tremendously overweighted in the share valuation.

Scanfil's has historically proven the ability to grow profitably and, in our view, the historical valuation has been driven mainly by the chronically difficult nature of the industry. Given the recent performance, a 13x-15x P/E ratio and a 10x-12x EV/EBIT ratio are easily acceptable levels for Scanfil. Therefore, relative to these levels the share price cannot be seen as too high, especially when the focus of pricing is already starting to shift toward next year. However, given the results of different methods, the share isn't particularly

cheap either, and we don't see much leeway in the ratios. The expected return that is based on earnings growth and dividends is on level with the equity return requirement.

In addition, investors receive a positive acquisition option, which we think is very likely in the mediumterm. In our estimate, the company has EUR 100 million of fire power in its balance sheet for M&A transactions that fit the current strategy and generate value to shareholders (i.e. valuation lower than own ratios). We are confident in this sense, given the company's track record with M&A transactions. Thus, the trade acquisition option swings the overall outlook of Scanfil to the positive side.

#### Peer group valuation is at a premium

When compared to the peer group that consists of global contract manufacturers, Scanfil's earnings-based valuation is at a 5-15 % premium. We see the premium justified, given Scanfil's performance of the past few years and positioning in industrial electronics with higher profitability potential. However, we don't see the valuation of peer companies as an important driver for Scanfil's valuation.


#### CMD can support the stock

Furthermore, we find it possible that Scanfil updates or raises its long term financial objectives in its CMD in September (2023 turnover organically EUR 700 million and adjusted operating profit 7%) and crystallizes the roadmap of its strategy. Thus, the news flow can be a driver for the stock in the near future.

Valuation	<b>2021</b> e	2022e	<b>2023</b> e
Share price	8.30	8.30	8.30
Number of shares, millions	64.5	64.5	64.5
Market cap	535	535	535
EV	546	521	503
P/E (adj.)	15.7	14.6	14.3
P/E	15.7	14.6	14.3
P/FCF	26.9	14.2	17.2
P/B	2.6	2.3	2.1
P/S	0.8	0.8	0.8
EV/Sales	0.8	0.8	0.7
EV/EBITDA	9.5	8.6	8.1
EV/EBIT (adj.)	12.6	11.1	10.4
Payout ratio (%)	35.9 %	36.9 %	39.7 %
Dividend yield-%	2.3 %	2.5 %	2.8 %

### Valuation table

Valuation	2016	2017	2018	2019	2020	2021e	2022e	2023e	2024e
Share price	3.49	4.28	3.75	4.89	6.52	8.30	8.30	8.30	8.30
Number of shares, millions	60.6	63.9	64.0	64.4	64.5	64.5	64.5	64.5	64.5
Market cap	221	273	240	313	420	535	535	535	535
EV	261	314	268	359	439	546	521	503	480
P/E (adj.)	13.6	10.6	8.3	9.8	13.0	15.7	14.6	14.3	13.8
P/E	neg.	10.6	8.3	11.2	11.4	15.7	14.6	14.3	13.8
P/FCF	14.5	36.4	10.5	77.0	8.3	26.9	14.2	17.2	13.9
P/B	2.0	2.2	1.7	1.9	2.3	2.6	2.3	2.1	1.9
P/S	0.4	0.5	1.7	0.5	0.7	0.8	0.8	0.8	0.8
EV/Sales	0.5	0.6	0.4	0.6	0.7	8.0	0.8	0.7	0.7
EV/EBITDA	14.3	7.9	5.7	6.8	7.2	9.5	8.6	8.1	7.5
EV/EBIT (adj.)	11.6	10.0	7.1	9.1	11.2	12.6	11.1	10.4	9.6
Payout ratio (%)	neg.	27.3 %	5.7	34.2 %	29.7 %	35.9 %	36.9 %	39.7 %	41.7 %
Dividend yield-%	2.6 %	2.6 %	3.5 %	3.1 %	2.6 %	2.3 %	2.5 %	2.8 %	3.0 %



## Peer group valuation

Peer group valuation	Share price	Market cap	EV	EV/	EBIT	EV/EI	BITDA	EV	//S	P	<b>/E</b>	Dividend	yield-%	P/B
Company		MEUR	MEUR	2021e	2022e	2021e	2022e	2021e	2022e	2021e	2022e	2021e	2022e	2021e
Plexus	88.20	2132	2085	14.2	12.2	10.6	9.2	0.7	0.7	17.9	15.4			2.5
Venture Corporation	19.37	3526	2960	12.4	11.1	11.0	10.0	1.4	1.3	17.4	16.1	3.9	4.0	2.1
Universal Scientific	14.08	4070	3855	13.8	11.1	9.9	7.9	0.5	0.4	17.8	14.6	2.6	3.1	2.4
Siix	1404.00	545	714							10.8	9.7	2.1	2.3	1.1
Fabrinet	92.99	2899	2505	15.8	13.7	13.1	11.5	1.5	1.3	20.3	18.2			3.1
TT Electronics	285.00	583	686	15.8	13.2	11.1	9.6	1.2	1.2	19.1	15.8	2.0	2.3	1.7
Hana Microelectronics	75.75	1567	1312	20.6	18.2	12.6	11.5	1.9	1.7	26.9	24.9	2.2	2.4	2.8
Lacroix		191	241	10.2	8.7	6.3	5.3	0.4	0.4	12.1	10.6	2.4	2.8	1.3
Jabil	58.99	7271	8696	8.0	7.2	4.8	4.4	0.3	0.3	10.6	9.8	0.6	0.6	4.0
Foxconn	112.50	47484	43359	6.5	5.2	4.4	3.7	0.2	0.2	11.6	10.0	4.5	4.9	1.1
Flextronics	17.55	7242	8160	6.2	8.3	4.1	6.3	0.3	0.4	12.2	9.7			2.6
Celestica	10.85	930	1004	4.5	4.1	3.0	2.9	0.2	0.2	7.4	6.6			8.0
Pegatron	68.30	5553	6447	9.3	7.7	4.6	2.1	0.1	0.1	9.7	9.7	6.6	7.0	1.0
Kitron		336	402	14.2	11.9	10.7	9.2	1.0	0.9	16.1	14.1	4.1	4.8	3.8
Hanza	27.60	92	134	10.9	8.5	5.9	5.2	0.6	0.5	12.8	11.7	1.1	2.5	1.7
Incap	51.60	299	306	12.9	10.3	10.7	9.1	1.7	1.5	18.8	16.0	1.2	1.3	5.1
Scanfil (Inderes)	8.30	535	546	12.6	11.1	9.5	8.6	8.0	8.0	15.7	14.6	2.3	2.5	2.6
Average				11.7	10.1	8.2	7.2	8.0	0.7	15.1	13.3	2.8	3.2	2.3
Median				12.4	10.3	9.9	7.9	0.6	0.5	14.5	12.9	2.3	2.7	2.3
Diff-% to median				2%	8%	-4%	9%	44%	55%	9%	13%	0%	-6%	15%

Source: Thomson Reuters / Inderes. NB: The market cap Inderes uses does not consider own shares held by the company

## **Income statement**

Income statement	2019	Q1'20	Q2'20	Q3'20	Q4'20	2020	Q1'21	Q2'21	Q3'21e	Q4'21e	2021e	<b>2022</b> e	<b>2023</b> e	2024e
Revenue	579	144	156	142	154	595	163	173	164	172	672	680	695	710
Group	579	144	156	142	154	595	163	173	164	172	672	680	695	710
EBITDA	53.0	12.4	14.0	25.0	9.1	60.5	13.8	14.4	14.5	15.0	57.7	60.7	62.2	64.5
Depreciation	-17.7	-3.8	-3.8	-3.7	-4.8	-16.1	-3.8	-3.8	-3.4	-3.3	-14.3	-13.7	-13.8	-14.5
EBIT (excl. NRI)	39.3	8.6	10.2	9.9	10.4	39.1	10.0	10.6	11.1	11.7	43.4	47.0	48.4	50.0
EBIT	35.3	8.6	10.2	21.3	4.3	44.4	10.0	10.6	11.1	11.7	43.4	47.0	48.4	50.0
Group	39.4	8.6	10.2	21.3	4.3	44.4	10.0	10.6	11.1	11.7	43.4	47.0	48.4	50.0
Net financial items	-1.3	0.1	-0.6	-0.8	-1.3	-2.6	-0.7	-0.1	-0.3	-0.3	-1.3	-0.6	-0.5	-0.5
PTP	34.0	8.7	9.6	20.5	3.0	41.8	9.3	10.4	10.9	11.5	42.0	46.4	47.9	49.5
Taxes	-5.9	-1.2	-1.4	-2.4	0.1	-4.9	-1.7	-1.8	-2.2	-2.3	-8.0	-9.7	-10.5	-10.9
Minority interest	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net earnings	28.1	7.5	8.2	18.1	3.1	36.9	7.6	8.6	8.7	9.2	34.1	36.7	37.4	38.6
EPS (adj.)	0.50	0.12	0.13	0.12	0.14	0.50	0.12	0.13	0.13	0.14	0.53	0.57	0.58	0.60
EPS (rep.)	0.44	0.12	0.13	0.28	0.05	0.57	0.12	0.13	0.13	0.14	0.53	0.57	0.58	0.60
Key figures	2019	Q1'20	Q2'20	Q3'20	Q4'20	2020	Q1'21	Q2'21	Q3'21e	Q4'21e	<b>2021</b> e	<b>2022</b> e	<b>2023</b> e	<b>2024</b> e
Revenue growth-%	2.9 %	10.9 %	9.0 %	-7.0 %	-0.4 %	2.7 %	13.3 %	11.2 %	15.7 %	11.7 %	12.9 %	1.2 %	2.2 %	2.2 %
Adjusted EBIT growth-%	4.0 %	22.9 %	-0.5 %	-17.8 %	3.9 %	-0.5 %	16.3 %	3.9 %	12.1 %	12.5 %	11.0 %	8.3 %	3.0 %	3.3 %
EBITDA-%	9.1 %	8.6 %	9.0 %	17.6 %	5.9 %	10.2 %	8.5 %	8.3 %	8.8 %	8.7 %	8.6 %	8.9 %	8.9 %	9.1 %
Adjusted EBIT-%	6.8 %	6.0 %	6.6 %	7.0 %	6.8 %	6.6 %	6.1 %	6.1 %	6.8 %	6.8 %	6.5 %	6.9 %	7.0 %	7.0 %
Net earnings-%	4.9 %	5.2 %	5.3 %	12.8 %	2.0 %	6.2 %	4.7 %	5.0 %	5.3 %	5.3 %	5.1 %	5.4 %	5.4 %	5.4 %

## **Balance sheet**

Assets	2019	2020	<b>2021</b> e	<b>2022</b> e	<b>2023</b> e
Non-current assets	103	94.5	95.3	96.7	102
Goodwill	8.0	8.3	8.3	8.3	8.3
Intangible assets	16.8	14.3	14.4	14.5	14.6
Tangible assets	71.7	64.5	65.2	66.5	71.6
Associated companies	0.0	0.0	0.0	0.0	0.0
Other investments	0.5	0.5	0.5	0.5	0.5
Other non-current assets	0.0	0.0	0.0	0.0	0.0
Deferred tax assets	5.7	6.9	6.9	6.9	6.9
Current assets	237	245	275	278	288
Inventories	102	103	118	119	122
Other current assets	2.9	2.4	2.4	2.4	2.4
Receivables	112	113	128	129	132
Cash and equivalents	20.4	25.8	26.9	27.2	32.1
Balance sheet total	340	339	370	374	390


Liabilities & equity	2019	2020	<b>2021</b> e	2022e	<b>2023</b> e
Equity	167	183	206	230	254
Share capital	2.0	2.0	2.0	2.0	2.0
Retained earnings	122	153	176	201	224
Hybrid bonds	0.0	0.0	0.0	0.0	0.0
Revaluation reserve	0.0	0.0	0.0	0.0	0.0
Other equity	42.7	27.9	27.9	27.9	27.9
Minorities	0.0	0.0	0.0	0.0	0.0
Non-current liabilities	50.9	40.4	30.0	14.5	6.8
Deferred tax liabilities	7.0	5.7	5.7	5.7	5.7
Provisions	0.4	0.6	0.6	0.6	0.6
Long term debt	43.5	34.1	23.7	8.2	0.5
Convertibles	0.0	0.0	0.0	0.0	0.0
Other long term liabilities	0.0	0.0	0.0	0.0	0.0
Current liabilities	122	116	134	130	129
Short term debt	23.0	9.9	13.6	4.5	0.0
Payables	96.1	100	114	119	123
Other current liabilities	3.2	5.9	6.0	6.0	6.0
Balance sheet total	340	339	370	374	390

## **DCF** calculation

DCF model	2020	2021e	2022e	2023e	2024e	<b>2025</b> e	<b>2026</b> e	<b>2027</b> e	2028e	2029e	<b>2030e</b>	TERM
EBIT (operating profit)	44.4	43.4	47.0	48.4	50.0	51.2	51.2	52.0	51.9	52.2	53.2	
+ Depreciation	16.1	14.3	13.7	13.8	14.5	14.6	14.8	14.9	15.2	15.1	15.0	
- Paid taxes	-7.4	-8.0	-9.7	-10.5	-10.9	-11.3	-11.3	-11.5	-11.4	-11.5	-11.7	
- Tax, financial expenses	-0.3	-0.3	-0.1	-0.1	-0.1	0.0	0.0	0.0	0.0	0.0	0.0	
+ Tax, financial income	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
- Change in working capital	4.5	-14.5	1.9	-1.5	0.0	-3.4	-3.0	-6.4	-4.3	-4.4	-3.0	
Operating cash flow	57.3	35.0	52.7	50.1	53.5	51.1	51.7	49.0	51.4	51.3	53.4	
+ Change in other long-term liabilities	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
- Gross CAPEX	-6.7	-15.1	-15.1	-18.9	-15.1	-15.6	-15.6	-16.6	-14.6	-14.6	-15.2	
Free operating cash flow	50.8	19.9	37.6	31.1	38.4	35.5	36.1	32.4	36.8	36.7	38.3	
+/- Other	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
FCFF	50.8	19.9	37.6	31.1	38.4	35.5	36.1	32.4	36.8	36.7	38.3	709
Discounted FCFF		19.3	34.0	26.2	30.0	25.8	24.4	20.4	21.6	20.0	19.4	359
Sum of FCFF present value		600	581	547	521	491	465	440	420	398	378	359
Enterprise value DCF		600										

Equity value DCF per share	8.9
Equity value DCF	571
-Dividend/capital return	-11.0
-Minorities	0.0
+ Cash and cash equivalents	25.8
- Interesting bearing debt	-44.0
Enterprise value DCF	600
Sum of Ferr present value	000





#### Wacc

· · · · · · · · · · · · · · · · · · ·	
Tax-% (WACC)	20.0 %
Target debt ratio (D/(D+E)	10.0 %
Cost of debt	3.0 %
Equity Beta	1.10
Market risk premium	4.75%
Liquidity premium	0.85%
Risk free interest rate	2.0 %
Cost of equity	8.1 %
Weighted average cost of capital (WACC)	7.5 %





■ 2021e-2025e ■ 2026e-2030e ■ TERM

## **Summary**

Income statement	2018	2019	2020	<b>2021</b> e	<b>2022</b> e	Per share data	2018	2019	2020	<b>2021</b> e	<b>2022</b> e
Revenue	563	579	595	672	680	EPS (reported)	0.45	0.44	0.57	0.53	0.57
EBITDA	47.3	53.0	60.5	57.7	60.7	EPS (adj.)	0.45	0.50	0.50	0.53	0.57
EBIT	37.8	35.3	44.4	43.4	47.0	OCF / share	0.49	0.50	0.89	0.54	0.82
PTP	36.1	34.0	41.8	42.0	46.4	FCF / share	0.36	0.06	0.79	0.31	0.58
Net Income	28.9	28.1	36.9	34.1	36.7	Book value / share	2.26	2.59	2.84	3.20	3.57
Extraordinary items	0.0	-4.0	5.3	0.0	0.0	Dividend / share	0.13	0.15	0.17	0.19	0.21
Balance sheet	2018	2019	2020	2021e	2022e	Growth and profitability	2018	2019	2020	<b>2021</b> e	<b>2022</b> e
Balance sheet total	304	340	339	370	374	Revenue growth-%	6%	3%	3%	13%	1%
Equity capital	145	167	183	206	230	EBITDA growth-%	18%	12%	14%	-5%	5%
Goodwill	10.1	8.0	8.3	8.3	8.3	EBIT (adj.) growth-%	21%	4%	-1%	11%	8%
Net debt	28.2	46.1	18.3	10.5	-14.4	EPS (adj.) growth-%	12%	10%	1%	6%	8%
						EBITDA-%	8.4 %	9.1 %	10.2 %	8.6 %	8.9 %
Cash flow	2018	2019	2020	2021e	<b>2022</b> e	EBIT (adj.)-%	6.7 %	6.8 %	6.6 %	6.5 %	6.9 %
EBITDA	47.3	53.0	60.5	57.7	60.7	EBIT-%	6.7 %	6.1 %	7.5 %	6.5 %	6.9 %
Change in working capital	-9.7	-14.1	4.5	-14.5	1.9	ROE-%	21.5 %	18.1 %	21.1 %	17.5 %	16.8 %
Operating cash flow	31.2	32.4	57.3	35.0	52.7	ROI-%	20.0 %	16.6 %	19.3 %	18.5 %	19.3 %
CAPEX	-8.2	-43.3	-6.7	-15.1	-15.1	Equity ratio	47.6 %	49.0 %	53.9 %	<b>55.7</b> %	61.5 %
Free cash flow	22.9	4.1	50.8	19.9	37.6	Gearing	19.5 %	27.7 %	10.0 %	5.1 %	-6.3 %
Valuation multiples	2018	2019	2020	<b>2021</b> e	<b>2022</b> e						
EV/S	0.5	0.6	0.7	0.8	0.8						

**Dividend-%**Source: Inderes

EV/EBITDA (adj.)

EV/EBIT (adj.)

P/E (adj.)

P/E

5.7

7.1

8.3

1.7

3.5 %

6.8

9.8

1.9

3.1%

7.2

11.2

13.0

2.3

2.6 %

9.5

12.6

15.7

2.6

2.3 %

8.6

11.1

14.6

2.3

2.5 %

## Disclaimer and recommendation history

The information presented in Inderes reports is obtained from several different public sources that Inderes considers to be reliable. Inderes aims to use reliable and comprehensive information, but Inderes does not guarantee the accuracy of the presented information. Any opinions, estimates and forecasts represent the views of the authors. Inderes is not responsible for the content or accuracy of the presented information. Inderes and its employees are also not responsible for the financial outcomes of investment decisions made based on the reports or any direct or indirect damage caused by the use of the information. The information used in producing the reports may change quickly. Inderes makes no commitment to announcing any potential changes to the presented information and opinions.

The reports produced by Inderes are intended for informational use only. The reports should not be construed as offers or advice to buy, sell or subscribe investment products. Customers should also understand that past performance is not a guarantee of future results. When making investment decisions, customers must base their decisions on their own research and their estimates of the factors that influence the value of the investment and take into account their objectives and financial position and use advisors as necessary. Customers are responsible for their investment decisions and their financial outcomes.

Reports produced by Inderes may not be edited, copied or made available to others in their entirety, or in part, without Inderes' written consent. No part of this report, or the report as a whole, shall be transferred or shared in any form to the United States, Canada or Japan or the citizens of the aforementioned countries. The legislation of other countries may also lay down restrictions pertaining to the distribution of the information contained in this report. Any individuals who may be subject to such restrictions must take said restrictions into account.

Inderes issues target prices for the shares it follows. The recommendation methodology used by Inderes is based on the share's 12-month expected total shareholder return (including the share price and dividends) and takes into account Inderes' view of the risk associated with the expected returns. The recommendation policy consists of four tiers: Sell, Reduce, Accumulate and Buy. As a rule, Inderes' investment recommendations and target prices are reviewed at least 2–4 times per year in connection with the companies' interim reports, but the recommendations and target prices may also be changed at other times depending on the market conditions. The issued recommendations and target prices do not guarantee that the share price will develop in line with the estimate. Inderes primarily uses the following valuation methods in determining target prices and recommendations: Cash flow analysis (DCF), valuation multiples, peer group analysis and sum of parts analysis. The valuation methods and target price criteria used are always company-specific and they may vary significantly depending on the company and (or) industry.

Inderes' recommendation policy is based on the following distribution relative to the 12-month risk-adjusted expected total shareholder return.

Buy The 12-month risk-adjusted expected shareholder return of the share is very attractive

Accumulate The 12-month risk-adjusted expected shareholder return of the share is attractive

Reduce The 12-month risk-adjusted expected shareholder return of the share is weak

Sell The 12-month risk-adjusted expected shareholder return of the share is very weak

The assessment of the 12-month risk-adjusted expected total shareholder return based on the above-mentioned definitions is company-specific and subjective. Consequently, similar 12-month expected total shareholder returns between different shares may result in different recommendations, and the recommendations and 12-month expected total shareholder returns between different shares should not be compared with each other. The counterpart of the expected total shareholder return is Inderes' view of the risk taken by the investor, which varies considerably between companies and scenarios. Thus, a high expected total shareholder return does not necessarily lead to positive performance when the risks are exceptionally high and, correspondingly, a low expected total shareholder return does not necessarily lead to a negative recommendation if Inderes considers the risks to be moderate.

The analysts who produce Inderes' research and Inderes employees cannot have 1) shareholdings that exceed the threshold of significant financial gain or 2) shareholdings exceeding 1% in any company subject to Inderes' research activities. Inderes Oyj can only own shares in the target companies it follows to the extent shown in the company's model portfolio investing real funds. All of Inderes Oyj's shareholdings are presented in itemised form in the model portfolio. Inderes Oyj does not have other shareholdings in the target companies analysed. The remuneration of the analysts who produce the analysis are not directly or indirectly linked to the issued recommendation or views. Inderes Oyj does not have investment bank operations.

Inderes or its partners whose customer relationships may have a financial impact on Inderes may, in their business operations, seek assignments with various issuers with respect to services provided by Inderes or its partners. Thus, Inderes may be in a direct or indirect contractual relationship with an issuer that is the subject of research activities. Inderes and its partners may provide investor relations services to issuers. The aim of such services is to improve communication between the company and the capital markets. These services include the organisation of investor events, advisory services related to investor relations and the production of investor research reports.

More information about research disclaimers can be found at www.inderes.fi/research-disclaimer.

Inderes has made an agreement with the issuer and target of this report, which entails compiling a research report.

#### Recommendation history (>12 mo)

Date	Recommendation	Target price	Chara price
			Share price
8/9/2017	Reduce	4.50 €	4.44 €
10/30/2017	Accumulate	4.50 €	4.22 €
11/14/2017	Accumulate	4.50 €	4.18 €
12/13/2017	Accumulate	4.70 €	4.26 €
2/19/2018	Accumulate	4.85 €	4.30 €
4/16/2018	Accumulate	5.25€	4.88 €
4/27/2018	Accumulate	5.40 €	4.98 €
8/13/2018	Accumulate	5.40 €	4.81 €
10/29/2018	Accumulate	4.80 €	4.34 €
12/21/2018	Buy	4.50 €	3.52€
2/18/2019	Accumulate	4.50 €	4.24 €
4/26/2019	Accumulate	4.50 €	4.20 €
8/12/2019	Accumulate	4.50 €	4.04€
10/28/2019	Accumulate	4.75 €	4.35€
1/17/2020	Accumulate	5.25€	4.94 €
2/20/2020	Accumulate	5.60€	5.20€
3/23/2020	Accumulate	4.25 €	3.73 €
4/25/2020	Accumulate	5.00€	4.48 €
8/5/2020	Accumulate	5.50€	5.18 €
8/10/2020	Accumulate	6.00€	5.56€
10/28/2020	Buy	6.00€	5.14 €
12/15/2020	Accumulate	6.30€	5.96€
3/19/2021	Accumulate	7.30 €	6.90€
4/9/2021	Accumulate	8.00€	7.56 €
4/26/2021	Accumulate	8.60€	8.08€
6/14/2021	Accumulate	8.60€	8.06€
8/8/2021	Accumulate	8.75€	8.30€

# inde res.

Inderes' mission is to connect listed companies and investors. We produce high-quality research and content for the needs of our extensive investor community.

At Inderes we believe that open data is every investor's fundamental right. We guarantee investors' access to award-winning research, insightful video content and an active investor community.

For listed companies we ensure that there is always highquality information available on the company for investors and shareholders for decision making, and that data collected from investors can be utilized by the companies.

Over 100 Finnish listed companies want to serve their shareholders and investors through us by utilizing our company research services, data driven IR services, content creation and consulting.

#### **Inderes Oyj**

Itämerentori 2 FI-00180 Helsinki, Finland +358 10 219 4690

Award-winning research at inderes.fi







Juha Kinnunen 2012, 2016, 2017, 2018, 2019, 2020



Mikael Rautanen 2014, 2016, 2017, 2019



2012, 2016, 2018, 2019, 2020



Antti Viljakainen 2014, 2015, 2016, 2018, 2019, 2020



Petri Kajaani 2017, 2019, 2020



Joni Grönqvist 2019, 2020



Erkki Vesola 2018, 2020



Petri Gostowski 2020



Atte Riikola 2020



Olli Koponen 2020

# Research belongs to everyone.